Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
| ▸ | MMP12 | P39900 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23995725 | 0.83 | POLB (0.32) | — | |
| SCHEMBL527480 | 0.80 | FFAR3 (0.36) | FFAR3 | |
| SCHEMBL13252955 | 0.78 | L3MBTL1 (0.33) | — | |
| SCHEMBL14970349 | 0.78 | ALDH1A1 (0.36) | KDM4EHTT | |
| SCHEMBL19565874 | 0.76 | — | — | |
| SCHEMBL17031719 | 0.75 | CYP3A4 (0.35) | — | |
| SCHEMBL4535193 | 0.73 | ALDH1A1 (0.33) | — | |
| SCHEMBL4535192 | 0.73 | ALDH1A1 (0.33) | — | |
| SCHEMBL23344710 | 0.71 | — | — | |
| SCHEMBL5195803 | 0.70 | MEN1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9260414-B2 | Inhibitors of hepatitic C virus | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-02-16 | — | — | US | disclosed |
| US-20150071878-A1 | NOVEL INHIBITORS OF HEPATITIC C VIRUS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-03-12 | — | — | US | disclosed |
| US-20120122854-A1 | Carbocyclic Fused Cyclic Amines | BOEHRINGER MARKUS (CH) | 2012-05-17 | — | — | US | disclosed |
| US-7718679-B2 | Heteroaryl carboxamides | HOFFMAN-LA ROCHE INC. (US) | 2010-05-18 | — | — | US | disclosed |
| US-20080103143-A1 | NOVEL HETEROARYL CARBOXAMIDES | HOFFMANN-LA ROCHE INC. | 2008-05-01 | — | — | US | disclosed |
| US-20070049587-A1 | Factor Xa inhibitors | HOFFMANN-LA ROCHE INC. | 2007-03-01 | — | — | US | disclosed |
| US-20070015812-A1 | Factor Xa inhibitors | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049587-A1 | Factor Xa inhibitors | F12, F11, F10 | FFAR3 1110/4885KDM4E 2694/4885CA2 641/4885 |
| US-20150071878-A1 | NOVEL INHIBITORS OF HEPATITIC C VIRUS | HAVCR2, SLC10A1, HDGF | FFAR3 3552/4885KDM4E 3400/4885CA2 817/4885 |
| US-20120122854-A1 | Carbocyclic Fused Cyclic Amines | F12, F11, F2 | FFAR3 1565/4885KDM4E 2697/4885CA2 182/4885 |
| US-20070015812-A1 | Factor Xa inhibitors | F12, F11, F2 | FFAR3 1194/4885KDM4E 2728/4885CA2 1429/4885 |
| US-20080103143-A1 | NOVEL HETEROARYL CARBOXAMIDES | F12, F11, F2 | FFAR3 1558/4885KDM4E 1229/4885CA2 526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.